The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011

European Journal of Endocrinology

Volumn 171, Issue 4, 2014, Pages 519-526

  Tjörnstrand, Axel ^a,c   Gunnarsson, Kerstin ^a   Evert, Max ^a   Holmberg, Erik ^b   Ragnarsson, Oskar ^a,c   Rosén, Thord ^a,c   Filipsson Nyström, Helena ^a,c  

^a SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACROMEGALY; ACTH SECRETING ADENOMA; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; CUSHING DISEASE; FEMALE; GENDER; GROWTH HORMONE SECRETING ADENOMA; HUMAN; INCIDENCE; LIFETIME RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONFUNCTIONING PITUITARY ADENOMA; PROLACTINOMA; RISK; STANDARDISED INCIDENCE RATE; SWEDEN; THYROTROPIN SECRETING ADENOMA; TREND STUDY; WORLD HEALTH ORGANIZATION; ADENOMA; AGED; HYPOPHYSIS TUMOR; MIDDLE AGED; REGISTER; RETROSPECTIVE STUDY; SEX RATIO;

ACROMEGALY; ADENOMA; ADULT; AGE DISTRIBUTION; AGED; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INCIDENCE; MALE; MEDICAL RECORDS; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; PROLACTINOMA; REGISTRIES; RETROSPECTIVE STUDIES; RISK; SEX DISTRIBUTION; SWEDEN;

EID: 84907212726     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0144     Document Type: Article

References (24)

1. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA & Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. Journal of Clinical Endocrinology and Metabolism 2000 85 1420-1425. (doi:10.1210/jcem.85.4.6498)
2. Mindermann T & Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology 1994 41 359-364. (doi:10.1111/j.1365-2265.1994.tb02557.x)
3. Burrow GN, Wortzman G, Rewcastle NB, Holgate RC & Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. New England Journal of Medicine 1981 304 156-158. (doi:10.1056/NEJM198101153040306)
4. Teramoto A, Hirakawa K, Sanno N & Osamura Y. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology 1994 193 161-164. (doi:10.1148/radiology.193.1.8090885)
5. Faglia G. Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinologica 1993 129 (Suppl 1) 1-5.
6. Regal M, Paramo C, Sierra SM & Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clinical Endocrinology 2001 55 735-740. (doi:10.1046/j.1365-2265.2001.01406.x)
7. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004 101 613-619. (doi:10.1002/cncr.20412)
8. Raappana A, Koivukangas J, Ebeling T & Pirila T. Incidence of pituitary adenomas in northern Finland in 1992-2007. Journal of Clinical Endocrinology and Metabolism 2010 95 4268-4275. (doi:10.1210/ jc.2010-0537)
9. Ahmad OE, Lopez AD, Murray CJL, Lozano R & Inoue M Age standardization of rates: a new WHO standard. GPE discussion paper series 31, Geneva: World Health Organization, 2000.
10. Fay MPPR, Cronin KA, Le C & Feuer EJ. Age-conditional probabilities of developing cancer. Statistics in Medicine 2003 22 1837-1848. (doi:10.1002/sim.1428)
11. Fay M. Estimating age conditional probability of developing disease from surveillance data. Population Health Metrics 2004 27 6. (doi:10.1186/1478-7954-2-6)
12. Gruppetta M, Mercieca C & Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 2013 16 545-553. (doi:10.1007/s11102-012-0454-0)
13. Maurer RA. Estradiol regulates the transcription of the prolactin gene. Journal of Biological Chemistry 1982 257 2133-2136.
14. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006 65 265-273. (doi:10.1111/j.1365-2265.2006.02562.x)
15. Fernandez-Balsells MM, Murad MH, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Pérez L, Ponce de León-Lovatón PG et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism 2011 96 905-912. (doi:10.1210/jc.2010-1054)
16. Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, Vance ML & the Endocrine Society. Pituitary incidentaloma: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 894-904. (doi:10.1210/ jc.2010-1048)
17. Lindholm J, Juul S, Jorgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism 2001 86 117-123.
18. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, Croxson MS, Gamble GD, Hunt PJ & Toomath RJ. Mortality and morbidity in Cushing's syndrome in New Zealand. Clinical Endocrinology 2011 75 436-442. (doi:10.1111/j.1365-2265. 2011.04124.x)
19. Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology 2011 165 383-392. (doi:10.1530/EJE-11-0272)
20. Onnestam L, Berinder K, Burman P, Dahlqvist P, Engstrom BE, Wahlberg J & Filipsson Nyström H. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. Journal ofClinical Endocrinology and Metabolism 2013 98 626-635. (doi:10.1210/jc.2012-3362)
21. Ecemis GC, Atmaca A & Meydan D. Radiation-associated secondary brain tumors after conventional radiotherapy and radiosurgery. Expert Review of Neurotherapeutics 2013 13 557-565. (doi:10.1586/ern.13.37)
22. Cooper O & Melmed S. Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Practice & Research. Clinical Endocrinology & Metabolism 2012 26 447-460. (doi:10.1016/j.beem.2012.01.002)
23. Fernandez A, Karavitaki N & Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 2010 72 377-382. (doi:10.1111/j.1365-2265. 2009.03667.x)
24. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775. (doi:10.1210/jc.2006-1668)